Veradermics MANE
NYSE MANE
$116.74 -0.51 (-0.43%)
At close: Oct 2, 2026 · 4:00 PM EDT

Veradermics (MANE) Consolidated Net Income (2025 - 2026)

Updated

Veradermics' Consolidated Net Income came in at -$23.5 million for Q2 2026, compared with -$15.65 million a year earlier.

Analysis

Veradermics (MANE) Consolidated Net Income (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Veradermics reported Consolidated Net Income of -$78.78 million; for FY2025, it came in at -$70 million.

  • Going back by year, Consolidated Net Income was -$26.49 million in FY2024.
  • The five-year range for quarterly Consolidated Net Income is -$27.23 million (Q1 2026) to -$12.4 million (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 5.53 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.62 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.51 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -10.50 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -237.00 Mn
10 Veradermics 4.88 Bn 4.88 Bn - -23.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -23.50 Mn
Mar 31, 2026 -27.23 Mn
Jun 30, 2025 -15.65 Mn
Mar 31, 2025 -12.40 Mn
API Access

Veradermics Consolidated Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=MANE&period=max&api_key=YOUR_API_KEY